Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Valion Bio, Inc. (VBIO : NSDQ)

• Company Description    Valion Bio Inc. is a late-stage immunotherapeutics company. It offers Entolimod, which is a drug used to treat acute radiation syndrome. Valion Bio Inc., formerly known as Tivic Health Systems Inc., is based in SAN ANTONIO, United States. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $2.40 Daily Weekly Monthly 20 Day Moving Average: 872,530 shares Shares Outstanding: 0.89 (millions) Market Capitalization: $2.13 (millions) Beta: 1.79 52 Week High: $80.19 52 Week Low: $2.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -57.52% -56.90% 12 Week -83.13% -83.61% Year To Date -93.38% -94.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1305 E. Houston St. Building 1 Suite 311 - San Antonio,TX 78205 USA ph: 888-276-6888 fax: - None https://valionbio.com

• General Corporate Information    Officers Michael K. Handley - Chief Executive Officer Sheryle Bolton - Chairman Lisa Wolf - Chief Financial Officer Christina Valauri - Director Dean Zikria - Director Peer Information Valion Bio, Inc. (CORR.) Valion Bio, Inc. (RSPI) Valion Bio, Inc. (CGXP) Valion Bio, Inc. (BGEN) Valion Bio, Inc. (GTBP) Valion Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 918942202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 0.89 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.79 Market Capitalization: $2.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.09 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.91% vs. Previous Quarter: 2.69% Sales Growth vs. Year Ago Period: 15.87% vs. Previous Quarter: 69.77% ROE 06/30/26 - -193.17 03/31/26 - -140.86 12/31/25 - -115.12 ROA 06/30/26 - -67.10 03/31/26 - -64.94 12/31/25 - -72.66 Current Ratio 06/30/26 - 1.11 03/31/26 - 3.31 12/31/25 - 20.13 Quick Ratio 06/30/26 - 0.86 03/31/26 - 3.02 12/31/25 - 20.13 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -14,936.05 12/31/25 - - Book Value 06/30/26 - 25.57 03/31/26 - 88.10 12/31/25 - 166.26 Inventory Turnover 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Equity 06/30/26 - 1.74 03/31/26 - 0.62 12/31/25 - 0.38 Debt-to-Capital 06/30/26 - 38.33 03/31/26 - 27.11 12/31/25 - 21.08

Powered by Zacks Investment Research ©